Soaring Drug Prices in Europe: A Strain on Health Systems and Industry

By João L. Carapinha

October 15, 2024

A recent article from POLITICO Europe, titled “Drug prices in Europe are soaring — and are only expected to rise,” highlights several key points regarding the rising drug prices in Europe, particularly in the context of the pharmaceutical industry and regulatory changes.

Rising Drug Prices

Rising drug prices in Europe have significantly increased, particularly for cancer and rare disease medicines. Higher prices of these medicines, rather than an increase in the volume of drugs being purchased, drive this trend.

Impact on Health Insurance and Public Spending

European countries such as Germany, Spain, Belgium, and Latvia are experiencing higher expenditures on drugs due to these pricier medicines. Health insurance bodies and public health systems are feeling the strain of these rising drug prices.

Demographic and Market Factors

Demographic trends, including an aging population, contribute to the increased demand for expensive medicines. However, the primary driver of the cost increase is the high price of new treatments, especially those for cancer and rare diseases.

Regulatory Changes and Industry Reaction

The European Union is proposing changes to pharmaceutical rules, which include reducing the market exclusivity period for new medicines. This would allow unbranded (generic) competitors to enter the market sooner, potentially driving down prices. However, the pharmaceutical industry is strongly opposing these changes. They argue that they would reduce incentives for research and development and could lead to companies shifting their investments outside of Europe.

Industry Concerns and Economic Implications

Pharmaceutical companies and industry lobbyists argue that punitive pricing and regulatory hurdles are already challenging the industry in Europe. They fear that further reductions in market exclusivity periods could exacerbate the problem, leading to a decline in Europe’s position as a hub for pharmaceutical innovation and potentially causing companies to invest more in other regions like the U.S. or China.

Overall, the article underscores the tension between the need to control rising drug prices and the pharmaceutical industry’s concerns about the impact of regulatory changes on their ability to invest in research and development. Rising drug prices pose a significant challenge that requires a careful balancing act to ensure both affordability and innovation in the healthcare sector.

Reference url

Recent Posts

Collaboration Cardiac Surgery: Boosting Surgical Volumes Through Multidisciplinary Teams

By João L. Carapinha

September 1, 2025

Cardiovascular Business recently examines how closer collaboration cardiac surgery between interventional cardiologists and cardiac surgeons can increase patient referrals for surgical interventions. This is especially important as less-invasive procedures like transcatheter interventions grow in...
Mounjaro Price Increase UK: Impacts on Access and Health Economics
Eli Lilly is raising Mounjaro's UK price by 170% on September 1, 2025. The highest dose will jump from £122 to £330 monthly. But the company has negotiated discounts with pharmacies. This will lower the effective price to £247.50. This hike aims to align international pricing as it responds to pr...
Innovative Strategies of MoonLake Immunotherapeutics HS in Targeting Inflammatory Diseases

By João L. Carapinha

August 30, 2025

MoonLake Immunotherapeutics HS, under the leadership of CEO Jorge Santos da Silva, is reimagining traditional biotech strategies with a concentrated approach to immunotherapeutic drug development. Utilizing innovative nanobody technology, the company is making strides in treating inflammatory dis...